Grail (GRAL) closed at $115.89 on November 13, 2026, down 4.5% from the previous close, on volume of 342,409 shares (30-day average 943,542).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Nov 13, 2026 | Put with Delta Hedge | 15-Jan-27 90 P +7,650 Stock | 450 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | ||||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
GRAIL Earnings Call Highlights Galleri Growth and FDA Momentum
TipRanks (Sat, 14-Nov 8:44 PM ET)
Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL)
TipRanks (Tue, 10-Nov 7:36 AM ET)
GRAIL Reports Third Quarter 2026 Financial Results
PRNewswire (Wed, 4-Nov 4:02 PM ET)
GRAIL to Present at the UBS Global Healthcare Conference
PRNewswire (Tue, 27-Oct 4:02 PM ET)
GRAIL to Announce Third Quarter 2026 Financial Results
PRNewswire (Wed, 21-Oct 4:03 PM ET)
Globe Newswire (Fri, 9-Oct 11:55 AM ET)
GRAIL spotlights Galleri’s “more than 200 cancers” data ahead of two major October conferences
Market Chameleon (Tue, 6-Oct 3:07 AM ET)
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
PRNewswire (Mon, 5-Oct 4:01 PM ET)
GRAL jumps as FDA panel backs Galleri, with a 7–2 benefit-risk vote and unanimous safety support
Market Chameleon (Thu, 24-Sep 7:03 AM ET)
PRNewswire (Wed, 23-Sep 6:18 PM ET)
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Grail trades on the NASDAQ stock market under the symbol GRAL.
As of November 13, 2026, GRAL stock price declined to $115.89 with 342,409 million shares trading.
GRAL has a beta of 1.60, meaning it tends to be more sensitive to market movements. GRAL has a correlation of 0.04 to the broad based SPY ETF.
GRAL has a market cap of $5.21 billion. This is considered a Mid Cap stock.
Last quarter Grail reported $37 million in Revenue and -$2.21 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.13.
The top ETF exchange traded funds that GRAL belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
GRAL has outperformed the market in the last year with a return of +39.3%, while the SPY ETF gained +13.4%. In the last 3 month period, GRAL beat the market returning +69.8%, while SPY returned -2.8%. However, in the most recent 2 weeks GRAL has underperformed the stock market by returning -19.2%, while SPY returned -0.2%.
GRAL support price is $113.42 and resistance is $129.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRAL shares will trade within this expected range on the day.
